Mitsubishi Tanabe Pharma Pension Fund

Chairman Tokuno Shigenari holds the senior governance role as 理事長, while Managing Director and CIO Hiroki Masuoka is responsible for asset allocation and investment strategy execution. The fund operates under the oversight of its sponsor's corporate governance framework, which shifted in 2025 when Bain Capital acquired Mitsubishi Tanabe Pharma Corporation through K.K. BCJ-94.

The pension fund retains its separate legal identity and fiduciary obligations to plan participants. The acquisition changes the sponsor's ownership from public shareholders to private equity control, meaning the economic stakeholder relationship now runs through Bain Capital's portfolio company structure rather than a publicly traded parent. The fund's governance board continues to operate independently under Japanese pension law, but sponsor-level capital allocation decisions now sit with a private equity owner, which may influence long-term funding posture.

Specific asset allocation targets are not publicly disclosed. Japanese corporate pension funds of comparable profile typically allocate across domestic and foreign equities, Japanese government and corporate bonds, foreign fixed income, and a growing alternatives sleeve that includes private equity funds, real estate, and infrastructure. The CIO constructs the portfolio within risk parameters set by the fund's governing board, engaging external asset managers for most mandates.

Publicly available information does not clarify whether the fund engages in direct co-investments or operates solely through fund commitments. Most Japanese corporate pension funds of this scale delegate investment management to external institutions via separate account mandates or commingled fund vehicles, with limited direct deal activity. The fund's manager selection process is governed by Japanese fiduciary regulations under the Financial Instruments and Exchange Act.

The Mitsubishi Tanabe Pharma Pension Fund is specific to employees of Mitsubishi Tanabe Pharma Corporation and is not pooled with other Mitsubishi keiretsu entities. Each major Mitsubishi group company — including Mitsubishi Corporation, Mitsubishi Heavy Industries, and Mitsubishi UFJ Financial Group — maintains its own separate pension arrangements. The Tanabe Pharma fund operates independently with its own board, CIO, and investment policy.